Literature DB >> 1909304

Cellular mechanism of endothelin-1 release by angiotensin and vasopressin.

T Emori1, Y Hirata, K Ohta, K Kanno, S Eguchi, T Imai, M Shichiri, F Marumo.   

Abstract

Release of endothelin-1, a novel potent vasoconstrictor peptide originally isolated from endothelial cells, from cultured bovine endothelial cells has been shown to be stimulated by arginine vasopressin and angiotensin II. To elucidate the cellular mechanism by which endothelin-1 is released by these vasoconstrictors, we tested the effects of several compounds on the agonist-induced endothelin-1 release and studied the changes of cytosolic free Ca2+ concentrations and phosphoinositide breakdown by these agonists in cultured bovine endothelial cells. Protein kinase C inhibitors (H-7, staurosporine), an intracellular Ca2+ chelator, and an inhibitor of phospholipase C (neomycin), all abolished the agonist-induced endothelin-1 release, whereas the Ca2+ channel blocker nicardipine was ineffective. Although synthetic 1,2-diglyceride (diolein) dose dependently stimulated endothelin-1 release, downregulation of protein kinase C after pretreatment with phorbol ester resulted in decreased effects to increase endothelin-1 release by the agonists. Both arginine vasopressin and angiotensin II induced immediate and transient increases in intracellular Ca2+ levels of fura-2-loaded endothelial cells as well as formation of inositol trisphosphate; the agonist-induced intracellular Ca2+ increases were not affected either by nicardipine or by chelating extracellular Ca2+. The arginine vasopressin- and angiotensin II-induced intracellular Ca2+ increases, inositol trisphosphate formation, and endothelin-1 release were completely abolished by V1-receptor antagonist and saralasin, respectively. It is concluded that arginine vasopressin and angiotensin II stimulate the release of endothelin-1 by a common mechanism, involving receptor-mediated mobilization of intracellular Ca2+ and activation of protein kinase C in endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909304     DOI: 10.1161/01.hyp.18.2.165

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  25 in total

Review 1.  Physiology of endothelin and the kidney.

Authors:  Donald E Kohan; Edward W Inscho; Donald Wesson; David M Pollock
Journal:  Compr Physiol       Date:  2011-04       Impact factor: 9.090

Review 2.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  The renin-angiotensin-aldosterone system and cardiac ischaemia.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 5.  Vasopeptidase inhibition and endothelial function in hypertension.

Authors:  L V d'Uscio; T F Lüscher
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

6.  Differential effects of phosphoramidon on contractile responses to angiotensin II in rat blood vessels.

Authors:  L Chen; J R McNeill; T W Wilson; V Gopalakrishnan
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 7.  Endothelins. A potential target for pharmacological intervention in diseases of the elderly.

Authors:  H Lévesque; N Moore; N Cailleux; V Richard; C Thuillez; H Courtois
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

8.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

9.  Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.

Authors:  S M Gardiner; J E March; P A Kemp; J J Mullins; T Bennett
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.